0FY Stock Overview
A clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Equillium, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.74 |
| 52 Week High | US$2.71 |
| 52 Week Low | US$0.43 |
| Beta | 1.83 |
| 11 Month Change | -29.79% |
| 3 Month Change | -18.05% |
| 1 Year Change | 72.29% |
| 33 Year Change | -83.43% |
| 5 Year Change | -74.83% |
| Change since IPO | -93.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0FY | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -36.2% | -0.2% | 0.8% |
| 1Y | 72.3% | -16.9% | 9.1% |
Return vs Industry: 0FY exceeded the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: 0FY exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| 0FY volatility | |
|---|---|
| 0FY Average Weekly Movement | 20.5% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0FY's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0FY's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 45 | Bruce Steel | www.equilliumbio.com |
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company’s lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications.
Equillium, Inc. Fundamentals Summary
| 0FY fundamental statistics | |
|---|---|
| Market cap | €25.01m |
| Earnings (TTM) | -€4.40m |
| Revenue (TTM) | €43.80m |
0.6x
P/S Ratio-5.7x
P/E RatioIs 0FY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0FY income statement (TTM) | |
|---|---|
| Revenue | US$45.91m |
| Cost of Revenue | US$0 |
| Gross Profit | US$45.91m |
| Other Expenses | US$50.53m |
| Earnings | -US$4.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 100.00% |
| Net Profit Margin | -10.05% |
| Debt/Equity Ratio | 0% |
How did 0FY perform over the long term?
See historical performance and comparison